February 10th, 2009
New York Times: These days, venture capitalists are ever more cautious with their money.
January 29th, 2009
Green Tech Media: It's the "Fat Boy of Feedstocks," says Jim Imbler, CEO of Zeachem, which hopes to use the trees to produce fuel.
January 29th, 2009
Earh2Tech: In an inauspicious building on a strip of offices in Menlo Park, Calif., I recently met with the team behind ZeaChem, a 25-person startup that’s using a common microbe found in termite guts and regular soil to breakdown trees and plants into the next-generation of ethanol.
January 28th, 2009
Green Tech Media: In Silicon Valley, the concern isn't over whether or not President Obama's stimulus package will work, but what the final bill in his package will contain, writes Josh Green, General Partner, Mohr Davidow Ventures.
January 28th, 2009
Tech Crunch: VirtuOz, a company that develops virtual support agents, has closed a $11.4 million Series B funding round led by Mohr Davidow Ventures, with Galileo Partners and Eric Hahn with Inventures Group also participating.
January 27th, 2009
Genome Web: The privately held firm now has rights to develop a non-invasive, cell-free fetal DNA test based on methods licensed from the lab of Stephen Quake.
January 22nd, 2009
VentureBeat: Because Facebook is the largest, fastest-growing network in the world, a big question is what other social networks are going to do to compete.
January 20th, 2009
EE Times: In a deal likened by company representatives to the relationship between Microsoft and IBM at the beginning of the PC boom, virtual system prototyping technology provider Vast Systems Technology Corp. said last week that NEC Electronics Corp.'s U.S. subsidiary has agreed to distribute Vast virtualization technology with automotive microcontrollers.
January 8th, 2009
VentureBeat: Poor termites. They’ll have no part in the ZeaChem facilities that may someday pump out millions of gallons of cellulosic ethanol, even though it’s the humble bug’s legacy that allowed it all to happen.
January 8th, 2009
Genome Web: While the public financing market has virtually dried up and most IPOs have been pulled over recent months, venture capital cash is still available to life science tool firms with innovative products and a compelling business strategy, a couple of venture capital investors told GenomeWeb Daily News.